FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The key to fibrinolysis and thrombolysis
1692PDF: 523HTML: 261 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
920PDF: 119HTML: 122Supplementary: 79Appendix: 79 -
PO150 | FACTOR XII DEFICIENCY IN THE SETTING OF RECURRENT THROMBOSIS AND EXTENDED VENOUS OBSTRUCTION: A CASE ANALYSIS L. Leoni1, G. Pata1, A. Domenighini1, L. Crippa2, T. D'aliberti1, G. Galimberti1, F. Paciullo1, P. Rovere Querini1 | 1Internal Medicine Unit; 2Coagulation Service Thrombosis Research Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
7PDF: 2 -
Anticoagulation in obese patients: challenges and strategies
2029PDF: 530HTML: 303XML: 186 -
PO22 | Early detection and management of PICC-related thrombosis in oncohematologic patients through serial ultrasound monitoring: a prospective observational study S. Laurenti, M. Schneeberger, G. Rosati, A. Pozzi, M. Padrini, R. Vacchelli, A. Morotti | University of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy
636PDF: 27 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
616PDF: 135 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1350PDF: 218HTML: 133Appendix: 119 -
PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY G. Gerotziafas1|3|4|5, S. Allakhverdieva6, P. Henrique Fernandes Do Carmo Las Casa1, P. Van Dreden1|2, J. Fareed3, N. Lomakin6 , I. Zotova6, L. Buryachkovskaya7 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; 2Clinical Research, Diagnostica Stago, Gennevilliers, France; 3Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 4Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 5VAS-European Independent Foundation in Angiology/Vascular Medicine Milan, Italy; 6Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 7Federal State Budgetary Institution «National Medical Research Centre of Cardiology Named After Academician E. I. Chazov» of the Ministry of Health of the Russian Federation, Moscow, Russia
455PDF: 104 -
Thrombin generation assay in COVID-19 patients shows a hypocoagulable pattern
2502PDF: 505Supplementary: 263 -
PO011 | A TWO CENTERS REAL-WORLD EXPERIENCE WITH ANTI-XA DIRECT ORAL ANTICOAGULANTS IN CANCER PATIENTS WITH UNUSUAL SITE VEIN THROMBOSIS U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Caputo2, M. Romano2, R. Russo2, R. Guarrasi3, M. Triggiani1, A. Tufano2, A. Guida4 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2Dipartimento di Medicina Interna, Università degli studi di Napoli Federico II, Italy; 3UOC Clinica Oncologica; 4Centro per le malattie emorragiche congenite e malattie trombotiche AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
6PDF: 2 -
OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou1, I. Diamandoulaki2, P. Baglaridis1, P. Las Casa3, P. Van Dreden4, K. Toutouzas1, G. Gerotziafas4|5 | 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; 2Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 4Diagnostica Stago, clinical research, Gennevilliers, France; 5Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
509PDF: 130 -
PO79 | Trying to hit the hit in the shadow of renal failure: a complex case managed with danaparoid S. Chessa1,2, M. Anedda2, M.V. Cherchi2, M. Vacca1,2, M. Caboni2, J. Pilia2, A.M. Bussu2, M. Mantega2, G. Costanzo1, D. Firinu1, S. Del Giacco1, A. Mameli3, D. Barcellona3 | 1Department of Medical Science and Public Health, University of Cagliari; 2Internal Medicine, ASL Sulcis, PO Sirai, Carbonia; 3Department of Medical Sciences and Public Health, Hemostasis and Thrombosis Unit, University of Cagliari and AOU of Cagliari, Italy
656PDF: 10 -
PO59 | Efficacy and safety of different anticoagulant treatment regimens for isolated internal jugular vein thrombosis: a case series A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, S. Marucci2, D. Menichelli1, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
691PDF: 31 -
When a feminist platelet went to the convention of prostaglandins and thromboxanes
1260PDF: 163HTML: 186Italian version: 104 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
430PDF: 88 -
PO38 | PERICATHETER AND SYSTEMIC THROMBOSIS DURING CAR-T LYMPHOCYTAPHERESIS: INCIDENCE AND CLINICAL CORRELATES I. Pansini1|2, E. Galli1, A. Corrente2, N. Piccirillo1|2, M. Viscovo1|2, S. Hohaus1|2, P. Chiusolo1|2, F. Sorà1|2, S. Sica1|2 | 1Department of Laboratory and Hematologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Hematology Section, Department of Radiologic and Hematologic Sciences, Università Cattolica del Sacro Cuore, Rome, Italy
430PDF: 100 -
PO58 | TACKLING THE AWARENESS GAP IN CANCER-ASSOCIATED THROMBOSIS: IMPACT OF A BRIEF EDUCATIONAL INTERVENTION IN PATIENTS WITH GYNECOLOGICAL CANCERS P. Santini, F. Mancinetti, G. Fracassa, E. Fondi, E. Ianuà, A. D'Errico, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy
508PDF: 104 -
CO-73 | WHEN BLEEDING MIMICS THROMBOSIS: DIAGNOSTIC DELAY AND THROMBOTIC COMPLICATIONS IN ACQUIRED HEMOPHILIA A R. Tomasello1, M. Mattana1, S. Raso1, F. Schirò1, P. Polidori2, M.I. Di Lena3, F. La Gattuta4, M. Napolitano1 | 1Ematologia e malattie rare, PO Cervello di Palermo, Italy; 2Farmacia ospedaliera, PO Cervello di Palermo, Italy; 3Direzione medica, PO Cervello di Palermo, Italy; 4Radiologia interventistica, PO Villa Sofia di Palermo, Italy
31PDF: 10 -
PO31 | Comparative analysis of anticoagulant therapy in patients over 90 years old: vitamin K antagonists versus direct oral anticoagulants G. Sottilotta1, P. Arrigo2, S. Cuzzocrea1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie, Emostasi e Trombosi, Grande Ospedale Metropolitano di Reggio Calabria; 2Associazione Italiana Pazienti Anticoagulati, Sezione di Reggio Calabria; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
591PDF: 15 -
PO72 | CATHETER-RELATED THROMBOSIS VS. FIBROBLASTIC SLEEVE. INCIDENCE AND IMPACT IN ONCOLOGICAL AND HEMATOLOGICAL PATIENTS WITH PERIPHERALLY INSERTED CENTRAL CATHETER M. Nunziata1, S. Mangiacapra1, F.P. Damiano1, N. Iuliano1, V. Iorio1, R. Natale2, L. Santarpia2, M. Amitrano1 | 1Internal Medicine, A.O.R.N. San Giuseppe Moscati, Avellino, Italy; 2Internal Medicine, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy
515PDF: 120 -
Availability of direct oral anticoagulants testing among Italian anticoagulation clinics: a rapid evolution of clinical practice On behalf of the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies
867PDF: 101 -
PO76 | Thrombosis associated with midline in autoimmune patient: a case report on the use of apixaban in a real-world setting M.V. Cherchi, M. Anedda, S. Che, M. Vacca, M. Caboni, M. Mantega | Department of Internal Medicine, ASL Sulcis, Italy
590PDF: 28 -
PO121 | IMMUNOTHROMBOSIS AND MULTIPLE-SITE VENOUS THROMBOEMBOLISM IN ACUTE TOXOPLASMOSIS: A CASE REPORT A. Grembiale1, A. Sabena1, G. Dettori1, C. Grendene1, S. Grazioli1, S. Venturini2 | 1SOC Medicina Interna 2 - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy; 2SSD Malattie Infettive - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy
6PDF: 2 -
CO12 | Left internal carotid artery thrombosis in a patient with antiphospholipid antibody syndrome successfully treated with eculizumab A. Hoxha1, L. Nico2, F. Viaro3, L. Fabris1, Y.F. Herrera1, M. Munari4, C. Baracchini3, F. Causin2, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED, University of Padua; 2Neuradiology Unit, University Hospital of Padua; 3Stroke Unit, Neurology Department, University of Padua; 4Intensive Care Unit, University Hospital of Padua, Italy
678PDF: 21 -
CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY M. Marchetti1|2, T. Zollner1|2, O.C. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Roma, Roma, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Torino, Italy; 7Department of Medicine, University of Padua, Padova, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Roma, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
10PDF: 2 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
644PDF: 21 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
434PDF: 92 -
PO36 | Venous stenting for symptomatic iliac thrombosis: five-years experience of single center I. Nichele1, G. Marchesini1, L. Boi2, G. Carli1, A. Tosetto1 | 1Hemophilia and Thrombosis Center, Hematology Department, S. Bortolo Hospital, Vicenza; 2Radiology Department, Ospedale Ca’ Foncello, Treviso, Italy
622PDF: 26 -
OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY A. Ramírez1, A. Orozco2, A. Sánchez3, F. Villalpa1, S. Burgos2, G. Cesarman3, G. Rodríguez1, D. Vieyra2, J. Álvarez4, G.M. Flores3, S. González1, D. Martínez2, B. Cabello3, R. Espinoza3, O. Fernández3 | 1Myeloma-clinic Hematology service, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México City, México; 2Myeloma-clinic Hematology service, Instituto Nacional de Nutrición Salvador Zubirán, México City, México; 3Myeloma-clinic Hematology service, Instituto Nacional de Cancerologçia, México City, Mexico; 4Centro Médico Nacional 20 de Noviembre, México City, Mexico
492PDF: 107 -
PO113 | A STRANGE CASE OF RECURRENT ISOLATED DIGITAL ARTERIAL THROMBOSIS M.M. Poggi, D. Bruni | SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy
6PDF: 3 -
PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani1, C. Séguin2 | 1Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; 2Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada
482PDF: 97 -
PO067 | LONG‑TERM SAFETY AND EFFECTIVENESS OF VITAMIN K ANTAGONISTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A RETROSPECTIVE COHORT ANALYSIS G. Sottilotta1, G. Praticò1, D. Megalizzi1, F. Luise2 | 1UOSD Centro per le Microcitemie - Servizio Emostasi e Trombosi; 2Laboratorio Analisi, Grande Ospedale Metropolitano di Reggio Calabria, Italy
7PDF: 2 -
CO048 | PREDICTORS OF FIRST THROMBOTIC EVENTS AFTER MECHANICAL VALVE REPLACEMENT FOR RHEUMATIC HEART DISEASE: A RETROSPECTIVE COHORT STUDY FROM SALAM CENTER FOR CARDIAC SURGERY (SUDAN) N. Erba1|3, S. Abdelwahab Abdallah1, D. Poli3, M. Langer2, G. Portella2, E. Giovanella1, F. Masini1, P. Malerba2 | 1The Salam Centre for Cardiac Surgery, Emergency NGO, Khartoum, Sudan; 2Emergency NGO Milano, Italy; 3Federazione dei Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Anti trombotiche, Italy
7PDF: 2 -
CO-22 | CLINICAL FEATURES IN PATIENTS WITH NON-SEVERE HEMOPHILIA A: THE DISCOVERY SCORE PROPOSAL FOR PROPHYLAXIS PRESCRIPTION M.N.D. Di Minno1, E. Baldacci2, C. Biasoli3, A. Borchiellini4, F. Daniele5, P. Di Gregorio6, C. Gorio7, G. Malcangi8, E. Marchesini9, I. Ricca10, R. Santoro11, S. Siragusa12, M.R. Villa13, E. Zanon14, A. Tagliaferri15, A. Coppola15 | 1Hub Centre for Thrombotic and Hemorrhagic Disorders, Federico II University Hospital, Napoli, Italy; 2Haematology, University Hospital Policlinico Umberto I, Roma, Italy; 3Interdepartmental Simple Structure for the Management of Hemorrhagic and Thromboembolic Diseases, M. Bufalini Hospital, Cesena, Italy; 4Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 5Haemostasis and Thrombosis Service, Ospedale Civile dell'Annunziata, Cosenza, Italy; 6Transfusion Medicine Department, "SS. Annunziata" Hospital, Chieti, Italy; 7Pediatric Onco-Hematology Unit, Children's Hospital, ASST-Spedali Civili, Brescia, Italy; 8Haemophilia and Thrombosis Center, University Hospital Policlinico-Giovanni XXIII, Bari, Italy; 9Hemophilia Centre, SC Vascular and Emergency Department, University of Perugia, Italy; 10Centro Emofilia, Città della Salute e della Scienza, Torino, Italy; 11Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; 12Centro di Riferimento Regionale per le Emocoagulopatie Congenite, Palermo, Italy; 13Hematology Unit, Ospedale Santa Maria di Loreto, Napoli, Italy; 14Hemophilia and Thrombosis Center, University Hospital of Padua, Italy; 15Hemophilia and Thrombosis Center, Azienda Ospedaliera di Parma, Italy
33PDF: 11 -
PO066 | ONE IN TWO MILLION: A 'DOUBLE-HIT' CASE OF INFRARENAL VENA CAVA AGENESIS AND TRIPLE-POSITIVE ANTIPHOSPHOLIPID SYNDROME N. Portesi, S. Pontoglio, G. Martini | ASST Spedali Civili di Brescia, Italy
8PDF: 3 -
PO01 | MELANOMA-DERIVED EXTRACELLULAR VESICLES DRIVE VON WILLEBRAND FACTOR–DEPENDENT THROMBOSIS AND METASTASIS Y. Wang1|2, X. Liu1, T. Downar3, A. Topuz4, A. Bauer1, J. Kött1|5, K. Nekipelov6, S. Brenna7, G. Bendas6, B. Puig7, S. Schneider1, D. Fedosov4, C. Gorzelanny1 | 1Department of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 4Institute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany; 5Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Pharmaceutical Institute, University of Bonn, Bonn, Germany; 7Neurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
489PDF: 108 -
CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
674PDF: 27 -
PO65 | OVARIC CANCER PRESENTING WITH COLD-AGGLUTININ MEDIATED HEMOLYTIC ANEMIA, PULMONARY THROMBOEMBOLISM AND DEEP VEIN THROMBOSIS R. Cannas | Hemostasis and thrombosis Center, Ospedale Santissima Trinità, ASL Cagliari, Italy
532PDF: 116 -
CO007 | TPO-RECEPTOR AGONISTS AS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOTIC EVENT IN IMMUNE THROMBOCYTOPENIA PATIENTS WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY M. Biglietto, B. Mandelli, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, S. Truglia, C. Santoro | Sapienza, University of Rome, Italy
11PDF: 3 -
PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
505PDF: 109 -
PO28 | Long term effectiveness and safety of venous thromboembolism with fondaparinux: data from the start registry I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma, Roma; 4IRCCS NeuRomad, Pozzilli, Italy
634PDF: 12 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
756PDF: 22 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
608PDF: 25 -
CO006 | PREVALENCE OF GASTROINTESTINAL BLEEDING IN GLANZMANN THROMBASTHENIA PATIENTS: RESULTS OF A WORLDWIDE SURVEY E. Falcinelli1, L. Bury1, S. Morais2, M. de Oliveira2, M. Kannan3, M. Faranoush4, D. Desprez5, V. Jean-Baptiste6, C. Santoro7, C. Falaise8, P. Saultier8, M. Fiore9, C. Albayrak10, A. Sánchez11, J.M. Bastida12, A. Artoni13, G. Castaman14, K. Gomez15, R. Schutgens16, L. Spiezia17, M. Sridharan18, N. Butta19, P. Buur van Kooten Niekerk20, E. Leinøe21, B. Guillet22, C. Panagiotis23, S. Crivelli24, E. De Candia25, M. Lewandowska26, P. De Bonis27, G. Kenet28, F. Heubel-Moenen29, J. Payne30, L. Banov31, L. Puccetti32, M. Olivieri33, M. Chitlur34, M. Lambert35, A. Pecci36, D. Martínez-Carballeira37, E. Zetterberg38, J. Curnow39, M. Napolitano40, A. Morotti41, R.C. Santoro42, R. Johann43, S. Saulyte Trakymiene44, A. Falanga45, C. Casas46, E. Zanon47, J. Moppet48, N.M. Popa-Fotea49, P. Gresele1 | 1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy; 2Centro Hospitalar Universitário de Santo António, Portugal; 3Blood and Vascular Biology Research Lab, Department of Biotechnology, Central University of Tamil Nadu, India; 4Iranian Hemophilia and Thrombophilia Association, MAHTA, Iran; 5CRC MHC Hopital Universaitire de Strasbourg, France; 6CHRU de Tours, University Hospital of Tours, France; 7UOC Ematologia, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Italy; 8AP-HM Timone, Marseille, France; 9CHU Bordeaux, France; 10Mayıs University Medical Faculty Pediatric Hematology and Oncology Dept, Türkiye; 11Hospital Universitario Morales Meseguer – Centro Regional de Hemodonación, Murcia, Spain; 12Complejo Asistencial Universitario De Salamanca, Spain; 13Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 14Azienda Ospedaliera Universitaria Careggi Florence, Italy; 15Royal Free Hospital, London, UK; 16Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, UMC Utrecht, The Netherlands; 17University of Padova, Italy; 18Mayo Clinic, Rochester, USA; 19Hospital Universitario La Paz-IdiPAZ, Madrid, Spain; 20Aarhus University Hospital, Denmark; 21Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 22University Hospital of Rennes, France; 23Blood unit and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Greece; 24Ospedale L. Sacco e Polo Universitario, Milano, Italy; 25Università Cattolica del Sacro Cuore-Roma, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy; 26Indiana Hemophilia and Thrombosis Center Innovative Hematology, USA; 27IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; 28Sheba Medical Center, Israel; 29Department of Hematology Internal Medicine, Maastricht University Medical Center and Hemophilia Treatment Center Nijmegen Eindhoven Maastricht and CARIM, Maastricht University, Maastricht, Netherlands; 30Sheffield Children’s NHS foundation Trust, UK; 31Hemostasis and Thrombosis Unit, Gaslini Children’s Hospital, Italy; 32University Teaching Hospital of Siena, Italy; 33Pediatric Thrombosis and Hemostasis Unit, Dr. von Hauner Childreńs Hospital, LMU Munich, Munich, Germany; 34Children's Hospital of Michigan, USA; 35Children’s Hospital of Philadelphia, USA; 36IRCCS Policlinico San Matteo Foundation and University of Pavia, Italy; 37Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain; 38Department of Hematology, Coagulation Unit, Skane University hospital, Sweden; 39Westmead Hospital, Sydney, Australia; 40PROMISE Department, University of Palermo, Italy; 41AOU San Luigi Gonzaga Hospital, University of Turin, Italy; 42Hemostasis and Thrombosis, Az. Osp. Univ. Dulbecco, Catanzaro, Italy; 43Hospital Center of Le Mans, France; 44Vilnius University Hospital Santaros Klinikos, Lithuania; 45ASST Papa Giovanni XXIII, Bergamo, Italy; 46Hospital San José, Bogotà, Colombia; 47Haemophilia Center-General Medicine, Padova University Hospital, Padova, Italy; 48University Hospitals Bristol NHS Foundation Trust, UK; 49University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
7PDF: 2 -
PO155 | MANAGEMENT OF ANTICOAGULANT THERAPY IN IMMUNOTHROMBOSIS SECONDARY TO TOXOPLASMA INFECTION A. Grembiale1, A. Sabena1, G. Dettori1, C. Grendene1, S. Grazioli1, S. Venturini2 | 1SOC Medicina Interna 2 - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy; 2SSD Malattie Infettive - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy
8PDF: 2 -
PO63 | Atypical venous thrombosis in young patient with systemic lupus erythematosus and high-risk APL profile: provoked or not? E. Marrone, A. Parisi, G. Di Monda, F. Gallucci, D. Morelli, C. Romano, U. Malgeri, D. D’Auria, P. Morella | Internal Medicine Unit 3, Cardarelli Hospital, Naples, Italy
603PDF: 22 -
PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD J. Barker1, K. Libby1, C. Holmes2, K. Martin2 | 1University of Vermont Health System; 2Department of Medicine, University of Vermont, Burlington, VT, USA
452PDF: 105 -
The use of creatine and the development of deep vein thrombosis. A scoping review
9055PDF: 819Supplementary: 210 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1445PDF: 305HTML: 202Supplementary: 102 -
CO-37 | STEW-EFA STUDY: MULTICENTER EVALUATION OF ONE-STAGE AND CHROMOGENIC ASSAYS FOR EFANESOCTOCOG ALFA MEASUREMENT ON STAGO AND WERFEN PLATFORMS A.C. Molinari1, M. Marchetti2, A. Catalano3, L. Contino4, R. De Cristofaro5, A.B. Federici6, T. Martini7, I. Quaglia8, R. Rossi9, R. Santoro10, A. Tripodi11, A. Valpreda12 | 1Regional Reference Centre for Hemorrhagic Diseases, Department of Hemato-Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy; 2Department of Immunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy; 3Società per la Promozione dell'educazione Medica (S.P.E.Me), Italy; 4Hemostasis and Thrombosis Unit, AOU SS Antonio e Biagio e C Arrigo, Alessandria, Italy; 5Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia "Agostino Gemelli," Università Cattolica S. Cuore, Roma, Italy - Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemelli" Istituto di Ricerca e Cura a Carattere Scientifico, Roma, Italy; 6School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy; 7Hemophilia Centre, Immune-Hematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza", Torino, Italy; 8Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 9Laboratory of Clinical Chemistry and Hematology, University Hospital of Parma, Italy; 10Hemophilia, Hemostasis, and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; 11IRCCS Ca' Granda Maggiore Hospital Foundation and Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 12Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Turin, Italy, reference laboratory of the Regional Center for Hemostasis and Thrombosis.
24PDF: 13 -
PO81 | Direct oral anticoagulants in atypical site vein thrombosis: a single centre experience focused on cancer patients U. Mazzarelli1, A. Guida1, L. Agrelli1, M. Amato1, R. Guarrasi2, L. Santaniello2, C. Cardamone1, P. Vitale1, M. Triggiani1 | 1Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche UOC Clinica Immunologica e Reumatologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno; 2UOC Clinica Oncologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
631PDF: 23 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
794PDF: 19 -
PO130 | HEMORRHAGIC AND THROMBOTIC COMPLICATIONS DURING DOACS TREATMENT: THE IMPORTANCE OF A REGULAR AND PROLONGED FOLLOW-UP D. Barcellona1|2, A. Mameli2, S. Cornacchini2, P. Schirru2, L. Fenu2, V. Casu2, F. Marongiu1|2 | 1University of Cagliari, Italy; 2Haemostasis and Thrombosis Unit, Azienda Ospedaliero-Universitaria di Cagliari, Italy
6PDF: 2 -
CO065 | THROMBOTIC RISK IS NOT UNIFORM ACROSS APHERESIS SETTINGS: INSIGHTS FROM CAR-T LYMPHOCYTAPHERESIS AND AUTOLOGOUS STEM CELL COLLECTION I. Pansini1|2, G. Brizzi2, E. Galli1, A. Corrente2, P. Rea2, N. Piccirillo1|2, M. Viscovo1|2, S. Hohaus1|2, P. Chiusolo1|2, F. Sorà1|2, S. Sica1|2 | 1Fondazione Policlinico Universitario A. Gemelli, Italy; 2Università Cattolica del Sacro Cuore, Italy
10PDF: 2 -
PO80 | Heparin-induced thrombocytopenia: a monocentric experience with danaparoid L. D’Innocenzo, S. Sorrentino, M. De Siati, A. Ferretti, E. De Candia | Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy
693PDF: 13 -
PO35 | Cerebral veins thrombosis in patients with and without myeloproliferative neoplasm: a real life retrospective monocentric study I. Bertozzi, M.T. Sartori, M. Zerbinati, G. Libralon, A. Galbiati, P. Simioni | First Medical Clinic, Department of Medicine - DIMED, Università degli Studi di Padova, Italy
598PDF: 27 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
447PDF: 94 -
CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY L. Girardi1|2, W. Ageno3, L. Bertù1, C. Lodigiani4, L.A. Ciuffini4, M.C. Vedovati5, C. Becattini5, A. Sammarco6, G. Camporese6, G. Cuni1|7, C. Ambaglio7, M.P. Donadini1 | 1Research Center on Thromboembolic Diseases and Antithrombotic Treatment, Department of Medicine and Surgery, University of Insubria, Varese, Italy; 2Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada; 3Department of Medicine, University of Padua, Padova, Italy; 4Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 5Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy; 6Clinica Medica 1, Department of Medicine, DIMED, Padova University Hospital, Padova, Italy; 7Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
6PDF: 2 -
CO063 | NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A POTENTIAL PREDICTOR OF THROMBOSIS IN CLASSICAL HODGKIN LYMPHOMA: AN EXPLORATORY ANALYSIS M. Biglietto1, G.M. Assanto1|2, S. Palladino1, G. Annechini1, G.M. D'Elia2, M.S. De Propris1|2, I. Del Giudice1|2, A. Chistolini1 | 1Sapienza, University of Roma, Italy; 2AOU Policlinico Umberto I, Roma, Italy
6PDF: 2 -
CS01 | Elucidating the evil relationship of metabolic dysfunction–associated fatty liver disease with cardiovascular comorbidities: the complex interplay among hypercoagulability, inflammation and liver fibrosis G. Gagliardi, E. Campello, A. Napolitano, B. Stocco, C. Di Gesù, G. Gobbo, I. Condonato, M. Allegra, G. Camporese, P. Scarinzi, R. Pesavento, F. Bilora, C. Bulato, A. Benetti, C. Samà, C. Portinari, G. Antonello, C. Goffi, L. Di Daniel, A. Zambon, L. Fabris, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
817PDF: 20 -
PO104 | BLEEDING AND THROMBOTIC OUTCOMES DURING EXTENDED DIRECT ORAL ANTICOAGULANT THERAPY: AN EIGHT YEAR RETROSPECTIVE ANALYSIS G. Sottilotta1, G. Praticò1, S. Cuzzocrea1, D. Megalizzi1, F. Luise2 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano di Reggio Calabria, Italy; 2Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
6PDF: 2 -
CO114 | ANTI-PS/PT IgM IDENTIFIES AN ANTIGEN-DEFINED SUBSET WITHIN LUPUS ANTICOAGULANT POSITIVITY ASSOCIATED WITH THROMBOTIC PHENOTYPE M. Sacco1, S. Lancellotti1, A. Ferretti1, M. Basso1, C. Gavotti2, A. Ortolan2, V.A. Pacucci2, P. Calzoni3, L. Puccetti3, R. De Cristofaro1|4 | 1Center for Hemorrhagic and Thrombotic Diseases; 2Rheumatology and Clinical Immunology Unit, Fondazione Policl. Univ. Gemelli IRCCS, Roma, Italy; 3Azienda Ospedaliera-Universitaria Senese, Unità specialistica Coagulopatie Trombotiche ed Emorragiche, Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Università di Siena, Siena, Italy; 4Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Roma, Italy
7PDF: 2 -
CO07 | Real word management of anticoagulant therapy in brain metastasis: moving toward a multidisciplinary approach in complex cases E. Lotti1, C. Manneschi2, S. Fancelli2, F. Scolari1, F. Crudele1, D. Poli1, M. Berteotti1, D. Rossini3, S. Pillozzi2, L. Antonuzzo2,3, R. Marcucci1,3 | 1Disease Unit, Careggi University Hospital, Firenze; 2Oncology Unit, Careggi University Hospital, Firenze; <sup>3</sup>Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
619PDF: 20 -
PO111 | A RARE CASE OF ACUTE PROMYELOCYTIC LEUKAEMIA PRESENTING WITH A PURELY THROMBOTIC DISSEMINATED INTRAVASCULAR COAGULATION PHENOTYPE L. Colavolpe, M. Provisione, L. Appio, S. Tupputi, N. Mumoli | ASST Valle Olona, Busto Arsizio, VA, Italy
7PDF: 2 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
479PDF: 109
